Recent studies have shown the protective effect of SGLT2 inhibitors (canagliflozin, empagliflozin, and dapagliflozin) against cardiovascular disease and death in patients with type 2 diabetes mellitus (Wiviott et al., 2019a; Arnott et al., 2020); however, oral admission of canagliflozin could increase the risk of limb amputation (Matthews et al., 2019), while both dapagliflozin and empagliflozin exhibit no evidence of risk (Dicembrini et al., 2019). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.